The Clinical Impact of Comedonecrosis Within Intraductal Carcinoma of the Prostate

& nbsp;Context.& mdash;Intraductal carcinoma of the prostate (IDC-P) is considered a distinct form of aggressive prostate cancer where comedonecrosis, a grade 5 pattern, is occasionally present. Meanwhile, assigning a Gleason grade to IDC-P remains controversial. Objective.& mdash;To assess the clinical significance of necro-sis associated with IDC-P. Design.& mdash;We compared radical prostatectomy (RP) findings and oncologic outcomes in men with prostate cancer exhibiting IDC-P with (IDC-P & thorn;/N & thorn;) versus without (IDC-P & thorn;/N???) comedonecrosis. Results.& mdash;Of the 558 RPs examined, IDC-P was present in 213 cases (38.2%), including 167 (78.4%) with IDC-P & thorn;/ N??? and 46 (21.6%) with IDC-P & thorn;/N & thorn;. When comparing IDC-P & thorn;/N??? versus IDC-P & thorn;/N & thorn; cases, the presence of necrosis was significantly associated with higher tumor grade, higher incidence of pT3/pT3b or pN1 disease, and larger estimated tumor volume. Outcome analysis revealed a significantly higher risk of disease progression in IDC-P & thorn;/N & thorn; patients than in IDC-P & thorn;/N??? patients (P < .001). Significant differences in progression-free survival between IDC-P & thorn;/N??? and IDC-P & thorn;/N & thorn; patients were also seen in subgroups, such as those without (P 1/4 .01) or with (P 1/4 .03) adjuvant therapy immediately after RP, those with pN0 disease (P < .001), and, more interestingly, those exhibiting conventional Gleason pattern 5 component (P 1/4 .02). Multivariate analysis showed significance for IDC-P & thorn;/ N & thorn; when IDC-P (grade 4) and IDC-P & thorn;/N & thorn; (grade 5) were (hazard ratio, 1.768; P 1/4 .049) or were not (hazard ratio, 2.000; P 1/4 .008) incorporated into the Gleason score. Conclusions.& mdash;IDC-P & thorn;/N & thorn; was found to be associated with worse histopathologic features on RP and poorer prognosis as an independent predictor. Pathologists may thus need to report the presence or absence of not only IDC-P but also comedonecrosis within IDC-P. (Arch Pathol Lab Med. 2023;147:94 & ndash;99; doi: 10.5858/ arpa.2021-0346-OA) <comment>Superscript/Subscript Available</comment